Beschreibung
Empagliflozin and losartan can both reduce blood pressure and lower serum potassium/sodium; combined use may increase the risk of dehydration, hypotension, and electrolyte imbalance.
Mechanismus
Empagliflozin causes osmotic diuresis via SGLT2 inhibition; losartan reduces aldosterone-mediated sodium retention and promotes potassium retention; combined volume loss and haemodynamic effects are additive.
Klinische Bedeutung
Clinical trials show that combining SGLT2 inhibitors with renin-angiotensin system blockers reduces cardiovascular events; acute kidney injury from volume depletion is a recognised risk.
Maßnahmen
Ensure adequate hydration; monitor renal function and electrolytes; counsel patients to hold empagliflozin during acute illness or surgery (sick-day guidance).
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.